Treatment
Cell clinical trials
We’re tracking 5,710 recruiting studies that include Cell, each written for real people, not researchers, below.
Recruiting studies
- NCT07523542RecruitingPhase 1/Phase 2
CAR-T Cell Therapy for Treatment-Resistant Lupus
This study tests a new type of immune cell therapy (CAR-T cells) designed to target and reduce the immune cells driving lupus in patients whose disease hasn't responded to standard treatments. Researchers will first identify which specific immune cells are causing your lupus, then engineer your own immune cells to fight them.
Shenzhen, GuangdongAges 18–70 - NCT07525466RecruitingPhase 1/Phase 2
New drug combination for NK/T-cell lymphoma with immune complications
This trial tests a combination of five drugs to treat a rare blood cancer called NK/T-cell lymphoma that has triggered an abnormal immune response (hemophagocytic lymphohistiocytosis). The goal is to control both the cancer and the harmful immune reaction.
BeijingAges 18 years+ - NCT07528105RecruitingEarly Phase 1
CAR-T Cell Therapy for Early-Stage Type 1 Diabetes
This early-stage trial tests a new type of immune cell therapy (CAR-T cells) designed to stop the body's immune system from attacking insulin-producing cells in type 1 diabetes. The goal is to help preserve remaining pancreas function in people with early-stage disease.
ShanghaiAges 18–40 - NCT07528352RecruitingPhase 1
Radiation Plus Antibody Therapy for Difficult-to-Treat Lymphoma
This trial tests a combination of radiation therapy to specific tumor sites followed by a bispecific antibody (a type of immunotherapy that targets cancer cells). It's designed for people with diffuse large B-cell lymphoma that has not responded to or has come back after at least two prior treatments.
Salt Lake City, UtahAges 18 years+ - NCT07529782RecruitingPhase 1
Safety and Efficacy of HDP-101 in Relapsed or Refractory Multiple Myeloma
This trial tests a new drug called HDP-101 in patients with multiple myeloma that has come back or stopped responding to previous treatments. The study aims to find the safest and most effective dose and to see if this drug can help control the cancer.
Beijing, Beijing MunicipalityAges Up to 18 years - NCT07540260Recruiting
Imaging-Guided Radiation Therapy for Advanced Kidney Cancer
This trial uses two types of PET scans to better target radiation therapy in patients with advanced clear cell kidney cancer that has spread or returned. The goal is to combine radiation with standard drug treatments to improve outcomes.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07540572RecruitingPhase 1
Testing IDE574 safety and effectiveness in advanced solid tumors
This early-stage trial tests a new drug called IDE574 to see if it is safe and effective in treating advanced cancers that have spread or stopped responding to standard treatments. The trial focuses mainly on hormone-receptor positive breast cancer, but also includes lung, prostate, and colorectal cancers.
Plantation, FloridaAges 18–99 - NCT07541391RecruitingPhase 1
CAR T-cell therapy for relapsed kappa myeloma
This trial tests a new treatment called CAR T-cells (your own immune cells engineered in the lab) designed to fight kappa-restricted multiple myeloma that has come back or stopped responding to standard drugs. The goal is to see if this treatment can help patients whose cancer has progressed despite previous therapies.
Melbourne, VictoriaAges 18 years+ - NCT07548060RecruitingPhase 2
New drug combination for advanced lung cancer after prior treatments
This trial tests two newer drugs (sacituzumab tirumotecan and furmonertinib) together for patients with advanced non-squamous lung cancer whose tumors have specific genetic mutations and have stopped responding to earlier EGFR-targeted drugs and chemotherapy. The goal is to find out if this combination can help patients whose cancer has progressed.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT07551362RecruitingPhase 1/Phase 2
CAR-NK Cell Therapy for Advanced Gastric Cancer
This trial tests a new type of cell therapy (CAR-NK cells) designed to attack gastric and esophageal junction cancers that have specific markers on their surface. The cells are engineered to recognize two targets on your cancer cells, which may help your immune system fight the cancer more effectively.
Shenzhen, GuangdongAges 18–75 - NCT07555431RecruitingPhase 2
Dolutegravir alone versus with tenofovir for HTLV-1
This study tests whether adding tenofovir (an antiviral medication) to dolutegravir helps treat HTLV-1 infection better than dolutegravir alone. HTLV-1 is a virus that can cause serious health problems, and researchers want to find the most effective treatment combination.
Salvador, Estado de BahiaAges 18 years+ - NCT07556497Recruiting
Blood cells and inflammation in diabetic heart disease
This study looks at why people with type 2 diabetes develop heart problems. Researchers will examine special cells in your blood and inflammation markers to better understand these complications.
DohaAges 18 years+ - NCT07556757RecruitingPhase 1
CD-19 T-cell therapy for relapsed B-cell leukemia in teens and adults
This study tests a new engineered cell therapy (CD-19 t-haNK) designed to fight back B-cell acute lymphoblastic leukemia (a blood cancer) in patients whose cancer has returned or stopped responding to standard treatment. The therapy uses specially modified immune cells to target and destroy leukemia cells.
JohannesburgAges 12 years+ - NCT07559019RecruitingPhase 1
Safety study of BI115 for advanced small cell lung cancer
This early-stage trial tests a new immunotherapy drug called BI115 in people with advanced small cell lung cancer (a fast-growing type of lung cancer). The study will check if the drug is safe and whether it helps slow or shrink the cancer.
Chongqing, Chongqing MunicipalityAges 18–75 - NCT07561567Recruiting
Breathing Control Device for Lung Cancer Radiation
This trial tests a new device that helps control your breathing during radiation therapy for early-stage lung cancer. By keeping your lungs still during treatment, the radiation is more accurate and may reduce side effects.
TianjinAges 18 years+ - NCT07561723RecruitingPhase 1
IMP3 Vaccine for Advanced Lung Cancer After Treatment Failure
This study tests a new vaccine designed to help your immune system fight advanced lung cancer that has not responded to standard treatments. The vaccine targets a protein called IMP3 found in your cancer cells.
Chengdu, SichuanAges 18 years+ - NCT07561957Recruiting
Smartphone app to help manage chronic kidney disease
This study tests a smartphone app designed to help people with chronic kidney disease (CKD)—a condition where the kidneys don't filter blood as well as they should—follow the latest medical guidelines. The app aims to make it easier for younger adults to stay on top of their kidney health and treatment.
DublinAges 16–30 - NCT07563738RecruitingPhase 1/Phase 2
ODM-212 with cancer immunotherapy for advanced solid tumors
This trial tests a new drug called ODM-212 combined with existing cancer treatments for mesothelioma, pancreatic cancer, or lung cancer with a specific genetic mutation. The study aims to find the right dose and see if adding ODM-212 helps these treatments work better.
Irving, TexasAges 18 years+ - NCT07564219Recruiting
Beta-Hydroxybutyrate to Boost CAR-T Cell Therapy in Multiple Myeloma
This trial tests whether a natural metabolite called beta-hydroxybutyrate can strengthen CAR-T cell therapy (a type of cancer-fighting cell treatment) in multiple myeloma patients. The goal is to help your immune cells work better against your cancer.
Hamburg, Free and Hanseatic City of HamburgAges 18 years+ - NCT07564401RecruitingPhase 1/Phase 2
CAR-T Cell Therapy for Advanced Lung Cancer
This study tests DJI136, a new type of cell therapy that trains your immune cells to fight small cell lung cancer. The therapy targets a protein called DLL3 found on cancer cells. It's designed for patients whose cancer has returned or progressed after initial chemotherapy and immunotherapy.
Lexington, KentuckyAges 18 years+ - NCT07564557Recruiting
Guided surgery for small deep lung cancers
This trial tests a new surgical technique to remove small, early-stage lung cancers that are located deep within the lung tissue. The goal is to remove only the affected area while preserving as much healthy lung as possible.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT07568184Recruiting
New Exosome Treatment for Sudden Hearing Loss
This trial tests a new way to deliver anti-inflammatory medicine directly into the ear using tiny particle carriers called exosomes. It's designed for people who lost hearing suddenly without a clear cause and didn't improve with standard steroid pills.
Kafr ash Shaykh, EgyptAges 18–65 - NCT07572890RecruitingPhase 1
Experimental treatment study for chronic kidney disease
This research study tests an experimental treatment for people with chronic kidney disease who are not yet on dialysis. The goal is to see if the treatment is safe and how it affects kidney function.
Winter Park, FloridaAges 18–80 - NCT07573956RecruitingPhase 2/Phase 3
Fast versus standard radiation after head and neck cancer surgery
This trial compares two different radiation schedules after surgery for head and neck cancer. One schedule delivers radiation faster over fewer weeks, while the other uses the standard approach. The study tests whether the faster schedule works just as well while potentially reducing side effects.
Jhajjar, HaryanaAges 18–80
Common questions
- Are there clinical trials studying Cell?
- Yes. Clin2 currently lists 5,710 recruiting studies that include Cell, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Cell trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Cell an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Cell or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.